Results 51 to 60 of about 40,253 (233)

Systemic therapy for colorectal cancer [PDF]

Archive of Oncology, 2003
Colorectal cancer alone accounts for around 200,000 deaths in Europe and represents a significant health problem. Although about fifty percent of patients are cured by surgery alone, the other half will eventually die due to metastatic disease, which ...
Štabuc Borut
doaj   +1 more source

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]

, 2010
Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Heinemann, Volker, Hoff, Paulo M.
core   +1 more source

Adherens junction protein expression is associated with poor response to neoadjuvant FLOT chemotherapy and pro‐inflammatory tumor microenvironment in esophageal adenocarcinoma

International Journal of Cancer, EarlyView.
What's New? Esophageal adenocarcinoma (EAC) is an aggressive cancer with poor survival and variable response to perioperative chemotherapy. Although histopathological features correlate with outcomes, the relationship specifically between adherens junction (AJ) protein expression and treatment response in EAC remains uncertain.
Bastian Grothey, Heike Löser, Tillmann Bedau, Wolfgang Schröder, Christiane J. Bruns, Thomas Zander, Max Krämer, Reinhard Büttner, Alexander Quaas   +8 more
wiley   +1 more source

Mucocutaneous Adverse Effects of Methotrexate Toxicity: A Case Series

Journal of Nepal Medical Association
Methotrexate is a widely used medication in dermatology, rheumatology, and oncology. However, patient misunderstandings or attempts to expedite symptom relief can lead to overuse, resulting in severe toxicity. This case series presents five instances of
Bibek Subedi, Saraswoti Neupane, Sajana Bhandari, Sunil Timilsina, Sudarshan Pokhrel   +4 more
doaj   +1 more source

Pharmacokinetics of rac‐leucovorin vs [S]‐leucovorin in patients with advanced gastrointestinal cancer. [PDF]

British Journal of Clinical Pharmacology, 1994
1. The pharmacokinetics of [R]‐leucovorin ([R]‐LV), [S]‐leucovorin ([S]‐ LV) and the circulating metabolite [S]‐5‐methyltetrahydrofolate ([S]‐5‐ MTHF) were studied after administration of racemic LV and [S]‐LV in 21 subjects. 2. After intravenous infusion of 600 mg m‐2 rac‐LV (group 1, n = 7) or 300 mg m‐2 [S]‐LV (group 3, n = 7), the decay of [S]‐LV ...
R M, Mader, G G, Steger, B, Rizovski, A E, Sieder, G, Locker, M F, Gnant, R, Jakesz, H, Rainer   +7 more
openaire   +2 more sources

Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab [PDF]

, 2015
Background: The aim of our study was to evaluate whether a panel of biomarkers, prospectively analysed might be able to predict patients' clinical outcome more accurately than RAS status alone.
Abouelkhair, KM, Cascinu, S, Del Prete, M, Faloppi, L, Giampieri, R, Ibrahim, EM, Loretelli, C, Mandolesi, A, Maristella, B, Scarpelli, M, Scartozzi, M   +10 more
core   +3 more sources

Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa‐Based Regimen in Newly Diagnosed Primary CNS Lymphoma

International Journal of Cancer, EarlyView.
Primary central nervous system diffuse large B‐cell lymphoma (PCNS‐DLBCL) lacks an optimal first‐line induction strategy, particularly for older patients and those ineligible for intensive consolidation. In this retrospective cohort of 36 newly diagnosed patients, the rituximab + methotrexate + thiotepa (RMT) regimen as first‐line induction achieved ...
Haotian Wang, Jia Li, Luming Cao, Ying Zhang, Xin Wan, Xingtong Wang, Yangzhi Zhao, Zhaoxia Li, Chengqian Chen, Yang Song, Ou Bai   +10 more
wiley   +1 more source

Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan

BMC Cancer, 2023
Background Early-stage colorectal cancer had excellent outcomes after curative resection, typically. However, a perplexing survival paradox between stage II and stage III was noted.
Yen-Lin Yu, Wen-Ko Tseng, Chun-Kai Liao, Chien-Yuh Yeh, Hong-Hwa Chen, Yu-Hsuan Liu, Yu-Wei Liaw, Chung-Wei Fan   +7 more
doaj   +1 more source

Application of Multiple imputation in Analysis of missing data in a study of Health-related quality of life [PDF]

, 2011
When a new treatment has similar efficacy compared to standard therapy in medical or social studies, the health-related quality of life (HRQL) becomes the main concern of health care professionals and can be the basis for making a decision in patient ...
Zhu, Chunming
core   +1 more source

A simplified genomic profiling approach predicts outcome in metastatic colorectal cancer [PDF]

, 2019
The response of metastatic colorectal cancer (mCRC) to the first-line conventional combination therapy is highly variable, reflecting the elevated heterogeneity of the disease.
Belardinilli, Francesca, Bellavia, Diana, Bonfiglio, Caterina, Canettieri, Gianluca, Capalbo, Carlo, Cardinali, Beatrice, Colella, Mariarosaria, Colicchia, Valeria, Coppa, Anna, Cortesi, Enrico, Filetti, Marco, Giannini, Giuseppe, Infante, Paola, Longo, Flavia, Magri, Valentina, Malapelle, Umberto, Marchetti, Paolo, Mezi, Silvia, Milanetti, Edoardo, Nicolussi, Arianna, Paci, Paola, Pecorari, Silvia, Petroni, Marialaura, Pisapia, Pasquale, Prete, Alessandra, Raimondo, Domenico, Santoni, Matteo, Tessitore, Alessandra, Troncone, Giancarlo, Valentini, Virginia   +29 more
core   +2 more sources